EN DE
Watch Zydus Lifesciences Limited for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Zydus Lifesciences Limited (ZYDUSLIFE) fair value: what the stock is really worth

As of Nov 6, 2026: fair value (intrinsic value) of Zydus Lifesciences Limited stock ₹663, price ₹1,198, that is 44.7% below the price, quality 48 out of 100. Rating: strongly overvalued. Calculated from audited financials with 17 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare IN · ISIN INE010B01027

ZL Zydus Lifesciences Limited logo Some data Nov 6, 2026

Zydus Lifesciences Limited

ZYDUSLIFE · NSE
Very expensive, weak quality

Our calculation puts a fair price 45% below what the stock costs today.

Solidly profitable · 13.8% net margin (TTM)
Low debt
Revenue last quarter +29% vs. a year ago.
Quality 48/100
Expensive Growth (revenue 5y +13.5 %/yr in INR)
0.1% dividend yield · Token dividend
Moderate moat 59/100
Some data
Fair value ₹662.93 · Strongly overvalued (−44.7%)
Negative free cash flow
Trails peers (5/13)
⚠ Small free float

Risks from the AI analysis

🚩USFDA scrutiny on manufacturing sites🚩Patent suits from originators🚩Price erosion from named rivals
Watch Zydus Lifesciences Limited for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

₹1,287 ₹319.36 Fair Value ₹662.93 Jul 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.

How to read this chart

60‑month range ₹319.36 – ₹1,287 · fair‑value band ₹488.55 – ₹1,105 · the ₹1,198 price screens above the ₹662.93 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.

Follow Zydus Lifesciences in your weekly email

Every Wednesday you see whether Zydus Lifesciences is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products.

Show moreShow less

It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands.

The company also provides a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses, as well as in the therapeutic areas of pain management, neurology, metabolic disorder, and neurology.

In addition, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. Further, it develops and markets products for orthopaedic surgery, including pathologies affecting the hip and knee.

The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

Stock analysis

Zydus Lifesciences Limited (ZYDUSLIFE) currently trades at ₹1,198, while our model-based Fair Value estimate is ₹662.93, 45% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Growth Earnings group reads highest at a median of ₹1,075 per share, and 1 of the 17 models we run sit above the ₹1,198 price.

Bear case: the DCF Models group reads lowest at ₹141.34, and 16 of the 17 models stay below the price. Data coverage for this calculation is medium.

Scenario range: ₹488.55 (bear) to ₹1,105 (bull), the price of ₹1,198 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 48/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Zydus Lifesciences Limited reported revenue of ₹271B in FY2026 versus ₹151B in FY2022, a compound +15.8%/yr. Reported net income was ₹50.4B in FY2026, compounding +2.9%/yr from FY2022.

Key figures

Market cap ₹1.2T (≈ $12.8B) Large · P/E ratio 28.6 · P/S ratio 3.97 · EPS (TTM) ₹41.85 · Dividend yield 0.1% · Net margin 13.8% · Return on equity 14.7% · Return on assets (EBIT) 20.7%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 59 out of 100 (medium confidence).

What moves the price

The share trades about 4% below its 52-week high and 39% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at −45%, ZYDUSLIFE screens richer than that median.

Fair Value models

Bear ₹488.55 Fair Value ₹662.93 Bull ₹1,105
Price ₹1,198 · Downside -44.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then (₹24.62 per share) are deliberately not added. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV ₹336.31 ₹387.54 ₹430.80 74
Owner Earnings ₹70.50 ₹141.34 ₹259.14 73
Residual Income ₹297.02 ₹403.04 ₹671.98 73
All 17 models by family
DCF Models
Owner Earnings ₹70.50 ₹141.34 ₹259.14 73
Earnings-Based
Graham-Dodd ₹343.58 ₹1,795 ₹2,484 63
Lynch FV ₹492.33 ₹703.32 ₹914.32 61
PEG = 1.0 ₹492.33 ₹703.32 ₹914.32 57
EPV ₹336.31 ₹387.54 ₹430.80 74
Dividend Discount
Gordon GGM ₹90.56 ₹169.54 ₹241.46 67
DDM Multi-Stage ₹90.56 ₹151.72 ₹180.34 67
Multiples
P/E Multiple ₹833.68 ₹1,112 ₹1,389 63
P/S Multiple ₹644.21 ₹858.94 ₹1,074 58
P/B Multiple ₹328.31 ₹437.75 ₹547.19 55
EV/EBIT ₹628.57 ₹875.11 ₹1,122 66
EV/EBITDA ₹646.25 ₹898.69 ₹1,151 67
EV/Revenue ₹416.83 ₹643.07 ₹869.31 53
Asset-Based
NCAV (Graham) ₹48.64 ₹65.18 ₹97.28 54
Economic Profit
Residual Income ₹297.02 ₹403.04 ₹671.98 73
ROIC Compounder ₹365.30 ₹489.07 ₹641.31 72
Growth Earnings
Growth-Adj P/E ₹752.37 ₹1,075 ₹1,397 67

The fair value above starts from this blend and is adjusted for a year distorted by one-off effects.

Open the full fair value analysis →

Quality Score breakdown

Overall quality 48/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 58
How much profit the company makes from its sales and capital
Quality Growth 34
Are margins and returns getting better?
Cashflow 10
Do the profits arrive as real cash?
Financial strength 73
Debt, balance sheet and risk of trouble
Investment 21
Does it invest with discipline instead of growing at any price?
Low Volatility 90
How calm the share price moves, does not count
Price momentum 62
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 72
Distance to the 52-week high, does not count
New shares 83
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 62/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+16.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+16.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.5%
Start year 2021 (pandemic). Over 10 years: +11.2% a year
Revenue growth 22 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.2%
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+19.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year+19.2%
Dividend (yield on the price)0.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.19.2% vs 13.2%, picking up
Profit margin 2004 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.16% → 21%
Pace: the 5-year rate starts in 2021 (pandemic)

ZYDUSLIFE screens overvalued: fair value 45% below the price. Compare with Merck KGaA →

Compare Zydus Lifesciences Limited with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 548 stocks

Beats the industry median on 5/13 measures
Overall it trails its industry peers.
Valuation
Quality Score 48 · Below median
Fair Value upside −44.7% · Below median
Profitability
Return on equity (12 months) 14.7% · Top 25%
Return on assets 9.6% · Top 25%
Net margin (12 months) 13.8% · Above median
Operating margin (12 months) 14.6% · Above median
Growth and dividend
Revenue growth (quarter YoY) 29.2% · Top 25%
Dividend yield (12 months) 0.1% · Bottom 25%
Balance sheet
Debt / equity 0.12× · Above median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/E (12 months) 28.6× · Pricier than median
P/B 4.45× · Priciest 25%
P/S (12 months) 3.97× · Pricier than median
EV/EBITDA 17.1× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 14
FUTURE (revenue growth)100 · sector 25
PAST (return on equity)59 · sector 29
HEALTH (low debt)94 · sector 96
DIVIDEND (yield)2 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Zoetis Inc ZTS $82.11 $111.63 +36% vs ZYDUSLIFE
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥50.43 ¥55.21 +9% vs ZYDUSLIFE
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,860 ₹1,947 +5% vs ZYDUSLIFE
Haleon plc HLN $9.15 $8.61 −6% vs ZYDUSLIFE
Merck KGaA MRK €148.75 €109.18 −27% vs ZYDUSLIFE
Galderma Group GALD CHF 191.75 CHF 109.26 −43% vs ZYDUSLIFE
Takeda Pharmaceutical Company TAK $21.19 $11.34 −46% vs ZYDUSLIFE
Teva Pharmaceutical Industries Limited TEVA $41.78 $20.74 −50% vs ZYDUSLIFE
Sandoz Group SDZ CHF 83.78 CHF 39.70 −53% vs ZYDUSLIFE
Divi's Laboratories Limited DIVISLAB ₹10,321 ₹1,567 −85% vs ZYDUSLIFE

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Zydus Lifesciences Limited: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Zydus Lifesciences Limited Fair Value". https://www.fairvalue-calculator.com/stock/ZYDUSLIFE

Frequently asked questions

Is Zydus Lifesciences Limited (ZYDUSLIFE) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of ₹662.93 versus a price of ₹1,198, about 45% lower (overvalued).
What is the fair value of ZYDUSLIFE?
Our model-based fair value for Zydus Lifesciences Limited is ₹662.93 (as of Nov 6, 2026), built from audited fundamentals. The current price: ₹1,198.
What is the quality score of ZYDUSLIFE?
Zydus Lifesciences Limited has a Quality Score of 48/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Zydus Lifesciences Limited (ZYDUSLIFE)?
Our model-based price target is the fair value of ₹662.93 (as of Nov 6, 2026) from 17 valuation models. Cautious scenario ₹488.55, optimistic scenario ₹1,105. It is a calculation from audited fundamentals, not an analyst target.
What is the Zydus Lifesciences Limited stock forecast for 2026?
Our models put fair value at ₹662.93, about 45% lower versus a price of ₹1,198 (overvalued). Cautious scenario ₹488.55, optimistic scenario ₹1,105. The calculation is refreshed regularly with new filings.
What is the revenue of Zydus Lifesciences Limited (ZYDUSLIFE)?
Zydus Lifesciences Limited reported trailing-twelve-month revenue of about ₹304B (latest available figure, as of Nov 6, 2026).
Does Zydus Lifesciences Limited pay a dividend?
Zydus Lifesciences Limited currently shows a dividend yield of 0.08% relative to its recent price (as of Nov 6, 2026).
What is the intrinsic value of Zydus Lifesciences Limited (ZYDUSLIFE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Zydus Lifesciences Limited it is ₹662.93 per share (as of Nov 6, 2026), against a price of ₹1,198. It is the blended result of 17 valuation models (cash flow, earnings, asset, dividend).
Is Zydus Lifesciences Limited stock overvalued or undervalued in 2026?
As of Nov 6, 2026, ZYDUSLIFE trades above its calculated fair value: price ₹1,198, fair value ₹662.93, a gap of about −45% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ZYDUSLIFE?
No. The price is what the market pays today (₹1,198); the fair value is what the company's own numbers justify (₹662.93). For Zydus Lifesciences Limited the two are ₹534.97 per share apart. That gap is exactly why we show both numbers side by side.
How much is Zydus Lifesciences Limited worth?
The market values Zydus Lifesciences Limited at about ₹1.2T (market capitalisation, as of Nov 6, 2026). Per share that is ₹1,198; our models calculate a fair value of ₹662.93 per share.
What do the bullish and bearish scenarios say about ZYDUSLIFE?
Our models span a range for Zydus Lifesciences Limited: cautious scenario ₹488.55, base ₹662.93, optimistic ₹1,105 per share (as of Nov 6, 2026, price ₹1,198). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ZYDUSLIFE?
Zydus Lifesciences Limited trades at a price-to-earnings ratio of 28.6 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹662.93 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2017 to 2026), reported earnings: 21.5. Other multiples: P/B 4.5, P/S 4.0, EV/EBITDA 17.1.
How solid is the balance sheet of Zydus Lifesciences Limited (ZYDUSLIFE)?
Balance-sheet figures for Zydus Lifesciences Limited (as of Nov 6, 2026): return on equity 14.7%, debt of 0.12 per unit of equity. They feed the Quality Score of 48/100, which measures business quality independently of the share price.
How far is ZYDUSLIFE from its 52-week high?
Zydus Lifesciences Limited trades at ₹1,198, about 4% below its 52-week high of ₹1,246 and 39% above the low of ₹860.00 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of ₹662.93 is for.
Which stocks are comparable to Zydus Lifesciences Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Zydus Lifesciences Limited stock attractive at the current price?
The data as of Nov 6, 2026: price ₹1,198, calculated fair value ₹662.93 (−45%), Quality Score 48/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ZYDUSLIFE calculated?
We run Zydus Lifesciences Limited through 17 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹662.93, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5% above its aggregate fair value. Zydus Lifesciences Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Zydus Lifesciences Limited (ZYDUSLIFE)?
The closing price on Nov 6, 2026 was ₹1,198. Our model-based fair value is ₹662.93, about 45% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Zydus Lifesciences Limited right now?
The price sits above even our optimistic bull case (₹1,105). The favourable scenario is already priced in. Weak quality (48/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (₹488.55 to ₹1,105) leaves room in how you read the outcome.
Where does the earnings growth of Zydus Lifesciences Limited (ZYDUSLIFE) come from?
Earnings per share at Zydus Lifesciences Limited grew +12.9 % a year from 2015 to 2026. Broken into its drivers: revenue per share +11.1 %, EBIT margin −0.5 %, tax rate −1.6 %, residual (interest, one-offs) +3.8 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.

Key figures of Zydus Lifesciences Limited

How large is the market capitalisation of Zydus Lifesciences Limited (ZYDUSLIFE)?
The market capitalisation of Zydus Lifesciences Limited is ₹1.2T (≈ $12.8B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Zydus Lifesciences Limited (ZYDUSLIFE)?
The price-to-sales ratio of Zydus Lifesciences Limited is 3.97 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Zydus Lifesciences Limited (ZYDUSLIFE)?
Earnings per share at Zydus Lifesciences Limited are ₹41.85 (price ÷ EPS = P/E 28.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Zydus Lifesciences Limited (ZYDUSLIFE)?
The dividend yield of Zydus Lifesciences Limited is 0.1% (payout 2.4%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Zydus Lifesciences Limited (ZYDUSLIFE)?
The net margin of Zydus Lifesciences Limited is 13.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Zydus Lifesciences Limited (ZYDUSLIFE)?
The return on equity (ROE) of Zydus Lifesciences Limited is 14.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Zydus Lifesciences Limited (ZYDUSLIFE)?
On an EBIT basis the return on assets of Zydus Lifesciences Limited is 20.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Zydus Lifesciences Limited (ZYDUSLIFE)?
The operating margin of Zydus Lifesciences Limited is 14.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Zydus Lifesciences Limited (ZYDUSLIFE)?
Revenue at Zydus Lifesciences Limited is growing +29.2% versus a year earlier (3y avg +16.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Zydus Lifesciences Limited (ZYDUSLIFE)?
Earnings per share at Zydus Lifesciences Limited are growing −25.8% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Zydus Lifesciences Limited (ZYDUSLIFE) generate?
The free cash flow of Zydus Lifesciences Limited is −₹12.0B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Zydus Lifesciences Limited (ZYDUSLIFE) carry?
The net debt of Zydus Lifesciences Limited is ₹111B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Zydus Lifesciences Limited in the live analysis

One click puts Zydus Lifesciences Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.